PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab
Abstract
Authors
G. Giovannoni P. Vermersch B. Arnould N. Hakimi-Hawken L. Araujo S. Saubadu P. Truffinet S. Gourlain J. Msihid